Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by BioNTech SE
< Previous
1
2
Next >
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
August 05, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
July 30, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
July 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
June 24, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
May 29, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
May 21, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
May 17, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
May 06, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
April 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
April 07, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
March 20, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
March 20, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
March 11, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Planned Retirement of Sean Marett
March 07, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
March 06, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
February 08, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
January 31, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
January 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
December 21, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
December 18, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Inaugurate First African Site on December 18, 2023
December 12, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
November 06, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
October 26, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
October 23, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
October 23, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.